{
    "clinical_study": {
        "@rank": "74013", 
        "arm_group": [
            {
                "arm_group_label": "[Group 1] DA-7218", 
                "arm_group_type": "Experimental", 
                "description": "200mg, By mouth or orally (PO) & intravenous(IV) administration"
            }, 
            {
                "arm_group_label": "[Group 1] Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, By mouth or orally (PO) & intravenous(IV) administration"
            }, 
            {
                "arm_group_label": "[Group 2] DA-7218", 
                "arm_group_type": "Experimental", 
                "description": "400mg, By mouth or orally (PO) administration"
            }, 
            {
                "arm_group_label": "[Group 2] Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, By mouth or orally (PO) administration"
            }, 
            {
                "arm_group_label": "[Group 3] DA-7218", 
                "arm_group_type": "Experimental", 
                "description": "600mg, By mouth or orally (PO) administration"
            }, 
            {
                "arm_group_label": "[Group 3] Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, By mouth or orally (PO) administration"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a phase I clinical trial for evaluating the pharmacokinetics and\n      safety/tolerability of DA-7218 in healthy male volunteers."
        }, 
        "brief_title": "Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male Korean 19-45 years\n\n          -  Body weight:55-90kg, BMI:18.0-27.0\n\n        Exclusion Criteria:\n\n          -  Present condition or history of any clinically significant disease\n\n          -  Clinical evidence or history of GI disease or history of GI surgery\n\n          -  History of hypersensitivities, including drug allergies\n\n          -  AST (SGOT) or ALT (SGPT) > 1.5 times the upper normal limit\n\n          -  Systolic blood pressure : <100 mmHg or >160 mmHg\n\n          -  Diastolic blood pressure : <60 mmHg or >100 mmHg\n\n          -  Drug abuse within 2 months, or a positive reaction to an abusive drug or cotinine\n\n          -  Taken any ETC or herbal supplement within 2 weeks or any OTC or vitamin supplement\n             within 1 week\n\n          -  Participation in and administration of IP of another clinical trial within 2 months\n\n          -  Donation of whole blood within 2 months, or blood components within 1 month, or\n             receipt of blood transfusion within 1 month\n\n          -  Consumption of more than 21 units of alcohol/week or inability to abstain from\n             drinking during the study period\n\n          -  Smoking within 3 months\n\n          -  Taking caffeine- or grapefruit-containing products within 3 days\n\n          -  Plan to be pregnant, or not to use an appropriate method of contraception"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097043", 
            "org_study_id": "DA7218_PK_I"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "[Group 1] DA-7218", 
                    "[Group 2] DA-7218", 
                    "[Group 3] DA-7218"
                ], 
                "intervention_name": "DA-7218", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "[Group 1] Placebo", 
                    "[Group 2] Placebo", 
                    "[Group 3] Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Kyung Sang Yu, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Block-randomized, Double-blind, Placebo-controlled, Single-dose, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers", 
        "other_outcome": [
            {
                "measure": "Adverse events (subjective or objective symptoms)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days(group 1), 7 days(group 2,3)"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "14 days(group 1), 7 days(group 2,3)"
            }, 
            {
                "measure": "Physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "14 days(group 1), 7 days(group 2,3)"
            }, 
            {
                "measure": "12-lead ECG", 
                "safety_issue": "Yes", 
                "time_frame": "14 days(group 1), 7 days(group 2,3)"
            }, 
            {
                "measure": "Clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "14 days(group 1), 7 days(group 2,3)"
            }
        ], 
        "overall_contact": {
            "email": "ksyu@snu.ac.kr", 
            "last_name": "Kyung Sang Yu, M.D., Ph.D.", 
            "phone": "+82-2-2072-1920"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University College of Medicine / Seoul National University Hospital", 
            "last_name": "Kyung Sang Yu, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the concentration-time curve from time zero to the last quantifiable concentration by linear trapezoidal method", 
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097043"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "tmax, AUCinf, t1/2, CL/F, Vz/F (F; calculated in group 1)", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}